Table 1 Examples of immunotherapies in clinical trials for breast cancer
From: The role of Th17 cells in the pathogenesis and treatment of breast cancer
Method | Study | Breast Cancer Subtype | Phase | Trial id |
|---|---|---|---|---|
Vaccines | CD40L vector vaccine | Breast cancer | I | NCT02140996 |
Vaccines | HER2 vaccine | Breast cancer | I | NCT01376505 |
Vaccines | HER2 DC Vaccine | Breast cancer | I/II | NCT02061332 |
Vaccines | Poly ICLC | TNBC | I | NCT02427581 |
Vaccines | Trastuzumab + E75 | HER2 breast cancer | II | NCT01570036 |
Vaccines | Chemotherapy + DC vaccine | HER2-/ER + (phase II) and TNBC (phase I) | I/II | NCT02018458 |
Bispecific antibodies | 68Ga-IMP-288 + TF2 | CEA + / HER2- breast cancer | I/II | NCT01730612 |
PD-1 | Vinorelbine + Gemcitaine + Eribulin + Capecitabine + Pembrolizumab | TNBC | III | NCT02555657 |
PD-1 | PDR001 | TNBC | I/II | NCT02404441 |
PD-1 | Carboplatin + Gemcitabine + Nivolumab + Nab-Paclitaxel | Breast cancer | I | NCT02309177 |
PD-1 | Pembrolizumab | HER2 + breast cancer | I/II | NCT02129556 |
PD-1 | Nivolumab + Ipilimumab + Entinostat | HER2- breast cancer | I | NCT02453620 |
PD-1 | Poly ICLC + CDX-1401 + Pembrolizumab | TNBC | I/II | NCT02661100 |
PD-L1 | Atezolizumab + Entinostat | TNBC | I/II | NCT02708680 |
PD-L1 | Trastuzumab + Durvalumab | HER2 + breast cancer | I | NCT02649686 |
PD-L1 | Atezolizumab | TNBC | II | NCT02478099 |
PD-L1 | Placebo + Nab-Paclitaxel + Atezolizumab | TNBC | III | NCT02425891 |
PD-L1 | Durvalumab + Paclitaxel | TNBC | I/II | NCT02628132 |
CTLA-4 | Ipilimumab + MGA271 | TNBC | I | NCT02381314 |
CTLA-4 | Tremelimumab + MEDI4736 | HER2- breast cancer | II | NCT02536794 |
4-1BB | Avelumab + PF-05082566 | TNBC | II | NCT02554812 |
OX40 | MEDI6469 | Breast cancer | I/II | NCT01862900 |
LAG-3 | Paclitaxel + Placebo + IMP321 | Stage IV | II | NCT02614833 |